Kobuk Therapeutics
Kobuk Therapeutics is developing a biologics platform designed to reset the immune system to a healthy state in patients with autoimmune diseases while preserving protective immunity. The platform aims to selectively modulate pathogenic immune responses, offering a potential alternative to broad immunosuppressive regimens. The company is seeking partnership opportunities with biotechnology and pharmaceutical organizations.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Autoimmune diseases arise when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and organ damage. Existing treatments often rely on broad immunosuppression, which can leave patients vulnerable to infections and other complications while failing to restore long-term immune balance.
Solution
Kobuk Therapeutics is developing a biologics platform specifically designed to address autoimmune diseases by resetting the immune system to a healthy state while preserving protective immunity. The platform aims to selectively modulate pathogenic immune responses without compromising the body's ability to fight infections. This approach represents a potential shift from chronic immunosuppression toward immune restoration and durable disease modification.
Target Audience
Primary customers are biotechnology and pharmaceutical partners seeking novel autoimmune disease therapeutics, as well as clinical development organizations focused on immune-mediated conditions.
Features
- Biologics platform engineered to reset immune system function toward a healthy baseline
- Mechanism designed to preserve protective immunity while dampening autoreactive responses
- Pipeline targeting autoimmune disease indications where immune dysregulation is a central driver
- Therapeutic approach intended to offer an alternative to broad immunosuppressive regimens